AR098140A2 - Método para regular la expresión de un blanco con una construcción de nucleótidos y para tratar una condición patológica; método para preparar dicha construcción composición médica y célula que la contiene - Google Patents

Método para regular la expresión de un blanco con una construcción de nucleótidos y para tratar una condición patológica; método para preparar dicha construcción composición médica y célula que la contiene

Info

Publication number
AR098140A2
AR098140A2 ARP140103952A ARP140103952A AR098140A2 AR 098140 A2 AR098140 A2 AR 098140A2 AR P140103952 A ARP140103952 A AR P140103952A AR P140103952 A ARP140103952 A AR P140103952A AR 098140 A2 AR098140 A2 AR 098140A2
Authority
AR
Argentina
Prior art keywords
expression
construction
regulating
nucleotide
preparing
Prior art date
Application number
ARP140103952A
Other languages
English (en)
Inventor
Nguyen Tam
Shanklin John
Original Assignee
Brookhaven Science Ass Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brookhaven Science Ass Llc filed Critical Brookhaven Science Ass Llc
Publication of AR098140A2 publication Critical patent/AR098140A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • C12N15/8218—Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
    • C12N15/8247—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine involving modified lipid metabolism, e.g. seed oil composition
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe un método para regular la expresión de un blanco, que comprende proveer a una célula la construcción de nucleótido que comprende: una secuencia de nucleótido que forma un tronco (stem) y un giro (loop); en donde el giro comprende una primera secuencia de nucleótido que modula la expresión de un blanco; en donde el tronco comprende una segunda secuencia de nucleótido que modula la expresión de un blanco; y en donde el blanco modulado por la primera secuencia de nucleótido y el blanco modulado por la segunda secuencia de nucleótido pueden ser iguales o diferentes; y cultivar dicha célula. Se describe también un método para tratar una condición patológica vectores, métodos para regular la expresión del blanco, para preparar una construcción para regular un blanco, composiciones farmacéuticas y células que comprende la construcción de nucleótido utilizada en los métodos.
ARP140103952A 2007-03-21 2014-10-21 Método para regular la expresión de un blanco con una construcción de nucleótidos y para tratar una condición patológica; método para preparar dicha construcción composición médica y célula que la contiene AR098140A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89621207P 2007-03-21 2007-03-21

Publications (1)

Publication Number Publication Date
AR098140A2 true AR098140A2 (es) 2016-05-04

Family

ID=39766774

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP080101204A AR066194A1 (es) 2007-03-21 2008-03-25 Composiciones antisentido en horquilla combinadas y metodos para modular la expresion de un gen blanco en celulas
ARP110100994A AR080722A2 (es) 2007-03-21 2011-03-23 Metodo para regular la expresion de un blanco con una construccion de nucleotidos y para tratar un acondicion patologica
ARP140103952A AR098140A2 (es) 2007-03-21 2014-10-21 Método para regular la expresión de un blanco con una construcción de nucleótidos y para tratar una condición patológica; método para preparar dicha construcción composición médica y célula que la contiene

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ARP080101204A AR066194A1 (es) 2007-03-21 2008-03-25 Composiciones antisentido en horquilla combinadas y metodos para modular la expresion de un gen blanco en celulas
ARP110100994A AR080722A2 (es) 2007-03-21 2011-03-23 Metodo para regular la expresion de un blanco con una construccion de nucleotidos y para tratar un acondicion patologica

Country Status (13)

Country Link
US (2) US8796442B2 (es)
EP (1) EP2129680B1 (es)
JP (1) JP5759673B2 (es)
AR (3) AR066194A1 (es)
AU (1) AU2008228814B2 (es)
BR (1) BRPI0809130A8 (es)
CA (1) CA2681323A1 (es)
DK (1) DK2129680T3 (es)
ES (1) ES2538217T3 (es)
HU (1) HUE027018T2 (es)
PL (1) PL2129680T3 (es)
PT (1) PT2129680E (es)
WO (1) WO2008116094A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008116094A2 (en) 2007-03-21 2008-09-25 Brookhaven Science Associates, Llc Combined hairpin-antisense compositions and methods for modulating expression
WO2009140374A2 (en) 2008-05-13 2009-11-19 Gen-Probe Incorporated Inactivatable target capture oligomers for use in the selective hybridization and capture of target nucleic acid sequences
US20130136727A1 (en) * 2009-11-19 2013-05-30 President And Fellows Of Harvard College Angiogenin and Variants Thereof for Treatment of Neurodegenerative Diseases
US8785121B2 (en) 2010-07-08 2014-07-22 Bonac Corporation Single-stranded nucleic acid molecule for controlling gene expression
CN103052711B (zh) * 2010-08-03 2016-08-03 株式会社博纳克 具有含氮脂环式骨架的单链核酸分子
US8691782B2 (en) 2010-08-03 2014-04-08 Bonac Corporation Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton
ES2664992T3 (es) * 2010-12-02 2018-04-24 Daiichi Sankyo Company, Limited Polinucleótido monocatenario modificado
WO2013180038A1 (ja) 2012-05-26 2013-12-05 株式会社ボナック デリバリー機能を有する遺伝子発現制御用の一本鎖核酸分子
JP6486836B2 (ja) 2013-12-26 2019-03-20 学校法人東京医科大学 遺伝子発現制御のための人工ミミックｍｉＲＮＡおよびその用途
AU2014370829B2 (en) 2013-12-27 2021-03-11 Bonac Corporation Artificial match-type miRNA for controlling gene expression and use therefor
SG11201705223XA (en) 2014-12-27 2017-07-28 Bonac Corp NATURALLY OCCURING miRNA FOR CONTROLLING GENE EXPRESSION, AND USE OF SAME
CN108064289A (zh) 2015-03-27 2018-05-22 株式会社博纳克 具有递送功能和基因表达调控能力的单链核酸分子

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453566A (en) * 1986-03-28 1995-09-26 Calgene, Inc. Antisense regulation of gene expression in plant/cells
JPH0813274B2 (ja) * 1990-08-13 1996-02-14 アイシス・ファーマシューティカルス・インコーポレーテッド 遺伝子発現を検出及び変調する糖修飾されたオリゴヌクレオチド
US6653458B1 (en) * 1993-09-03 2003-11-25 Isis Pharmaceuticals, Inc. Modified oligonucleotides
GB9710475D0 (en) * 1997-05-21 1997-07-16 Zeneca Ltd Gene silencing
US6395713B1 (en) * 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
TW589189B (en) 1997-08-04 2004-06-01 Scras Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis
US5952657A (en) * 1997-08-22 1999-09-14 Thermo Microscopes, Corp. Atomic force microscope with integrated optics for attachment to optical microscope
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
JP4187413B2 (ja) 1998-03-20 2008-11-26 コモンウェルス サイエンティフィック アンドインダストリアル リサーチ オーガナイゼーション 遺伝子発現の制御
PT1068311E (pt) 1998-04-08 2011-07-20 Commw Scient Ind Res Org Processos e meios de obter fenótipos modificados
US6106982A (en) 1998-05-11 2000-08-22 Avery Dennison Corporation Imaged receptor laminate and process for making same
AR020078A1 (es) 1998-05-26 2002-04-10 Syngenta Participations Ag Metodo para alterar la expresion de un gen objetivo en una celula de planta
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
WO2000044914A1 (en) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
DE19956568A1 (de) * 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US6160215A (en) * 1999-03-26 2000-12-12 Curtin; Lawrence F. Method of making photovoltaic device
AU781598B2 (en) 1999-04-21 2005-06-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for inhibiting the function of polynucleotide sequences
CN1360631A (zh) 1999-07-09 2002-07-24 美国家用产品公司 在质粒序列转录过程中防止畸变rna形成的方法和组合物
WO2001029058A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
DE10160151A1 (de) 2001-01-09 2003-06-26 Ribopharma Ag Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
DE10100586C1 (de) 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
AU1767301A (en) 1999-11-29 2001-06-04 Cold Spring Harbor Laboratory Regulation of polycomb group gene expression for increasing seed size in plants
RU2164944C1 (ru) * 1999-12-09 2001-04-10 Институт молекулярной биологии им. В.А. Энгельгардта РАН Способ изменения генетических свойств организма
IT1316982B1 (it) 2000-01-17 2003-05-26 Univ Roma Isolamento e caratterizzazione di un gene per il silenziamento genicoda n.crassa e suoi usi.
AU2001245793A1 (en) 2000-03-16 2001-09-24 Cold Spring Harbor Laboratory Methods and compositions for rna interference
WO2001070949A1 (en) 2000-03-17 2001-09-27 Benitec Australia Ltd Genetic silencing
AU2001260140A1 (en) 2000-03-22 2001-10-03 Avntis Pharma Deutschland Gmbh Nematodes as model organisms for the investigation of neurodegenerative diseases, in particular parkinsons disease, uses and methods for the discovery of substances and genes which can be used in the treatment of the above disease states and identification of a nematode gene.
GB0007268D0 (en) 2000-03-24 2000-05-17 Cyclacel Ltd Cell cycle progression proteins
WO2001092513A1 (en) 2000-05-30 2001-12-06 Johnson & Johnson Research Pty Limited METHODS FOR MEDIATING GENE SUPPRESION BY USING FACTORS THAT ENHANCE RNAi
ATE405585T1 (de) 2000-11-09 2008-09-15 Cenix Bioscience Gmbh Eukaryontische zellteilungsgene und deren verwendung in der diagnostik sowie in der behandlung von proliferativen erkrankungen
CZ308053B6 (cs) 2000-12-01 2019-11-27 Max Planck Gesellschaft Izolovaná molekula dvouřetězcové RNA, způsob její výroby a její použití
US20030130186A1 (en) * 2001-07-20 2003-07-10 Chandra Vargeese Conjugates and compositions for cellular delivery
US6566524B2 (en) * 2001-12-21 2003-05-20 The Procter & Gamble Co. Methods for synthesis of amino-tetrahydroisoquinoline-sulfonamide hydroxamic acids
US7576262B2 (en) * 2002-03-14 2009-08-18 Commonwealth Scientific And Industrial Research Organization Modified gene-silencing RNA and uses thereof
EP1348943A3 (en) * 2002-03-25 2003-12-17 Sysmex Corporation Sheath liquid for particle analyzer
US20040053876A1 (en) * 2002-03-26 2004-03-18 The Regents Of The University Of Michigan siRNAs and uses therof
US7387896B2 (en) * 2003-03-26 2008-06-17 The Regents Of The University Of Michigan MicroRNA vectors
WO2008116094A2 (en) 2007-03-21 2008-09-25 Brookhaven Science Associates, Llc Combined hairpin-antisense compositions and methods for modulating expression

Also Published As

Publication number Publication date
US20140342453A1 (en) 2014-11-20
JP5759673B2 (ja) 2015-08-05
EP2129680B1 (en) 2015-05-06
ES2538217T3 (es) 2015-06-18
CA2681323A1 (en) 2008-09-25
PT2129680E (pt) 2015-08-28
EP2129680A2 (en) 2009-12-09
AU2008228814B2 (en) 2014-03-06
US20080311658A1 (en) 2008-12-18
WO2008116094A3 (en) 2008-11-20
BRPI0809130A2 (pt) 2014-08-26
AR066194A1 (es) 2009-08-05
US9193972B2 (en) 2015-11-24
BRPI0809130A8 (pt) 2021-11-03
HUE027018T2 (en) 2016-08-29
DK2129680T3 (en) 2015-08-10
US8796442B2 (en) 2014-08-05
EP2129680A4 (en) 2010-10-20
PL2129680T3 (pl) 2015-10-30
AR080722A2 (es) 2012-05-02
AU2008228814A1 (en) 2008-09-25
JP2010521973A (ja) 2010-07-01
WO2008116094A2 (en) 2008-09-25

Similar Documents

Publication Publication Date Title
AR098140A2 (es) Método para regular la expresión de un blanco con una construcción de nucleótidos y para tratar una condición patológica; método para preparar dicha construcción composición médica y célula que la contiene
NZ763766A (en) Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators
UY38160A (es) Partículas implantables y métodos relacionados
PE20180743A1 (es) Metodo para produccion de l-aminoacido
BR112022004699A2 (pt) Vs-6063 em combinação com ch5126766 para o tratamento de câncer
BR112017007770A2 (pt) cultura in vitro, população de hipscs, método para modificar um locus-alvo genômico, e, hipsc.
ECSP14028704A (es) Métodos y composiciones para la modificación de adn objetivo dirigida por arn y para la modulación de la transcripción dirigida por arn
EA201591743A8 (ru) СТИМУЛЯТОРЫ sGC
AR069980A1 (es) Inmunoconjugados dirigidos contra cd 138 y sus usos
UY32030A (es) "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
CL2011002518A1 (es) Proceso para producir un vegetal, una semilla o su progenie, basado en transformar células vegetales con una secuencia de ácido nucleico que codifica una proteína quinasa relacionada con snf1, vector que comprende dicha secuencia; y métodos de aplicación.
BR112015020904A2 (pt) microrganismos e métodos para produção de butadieno e compostos relacionados por assimilação de formiato
MX2020003954A (es) Vectores lentivirales para suministro de pklr para el tratamiento de deficiencia de piruvato quinasa.
MX347112B (es) Composiciones y metodos para regular osmolaridad celular.
AR114504A1 (es) Regeneración de plantas genéticamente modificadas
AU2018337668A1 (en) Improved supraparticles
PH12018502061A1 (en) Differentiation of pluripotent stem cells to intestinal midgut endoderm cells
AR113122A1 (es) Método para mejorar la estabilidad en almacenamiento y aptitud biológica de esporas fúngicas
EA201891664A1 (ru) Составы/композиции, содержащие ингибитор btk
CO2018011586A2 (es) Inhibidor de esterasa c1 conjugado y sus usos
BR112017020513A2 (pt) método de produção de peixe para transplante, peixe para transplante, método de produção de espécie híbrida de peixe e espécie híbrida de peixe
MX2021011608A (es) Metodos ex vivo para producir celulas t terapeuticas y composiciones y metodos afines.
CO2021007006A2 (es) Moduladores de la expresión de irf5
ECSP21003171A (es) Dinucleótidos cíclicos como agonistas de sting
CL2020001108A1 (es) Mitoflavoscinas: la fijación como objetivo de enzimas que contienen flavina elimina células madre cancerosas (cscs) al inhibir la respiración mitocondrial.

Legal Events

Date Code Title Description
FC Refusal
FG Grant, registration